Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | MARS1 | P56192 | 10/20 | 0.36 |
| ▸ | BHMT | Q93088 | 2/20 | 0.36 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20996747 | 0.92 | RNPEP (0.42) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL162031 | 0.92 | RNPEP (0.42) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL6045793 | 0.92 | RNPEP (0.42) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL5617582 | 0.92 | RNPEP (0.42) | METAP2METAP1RNPEPMARS1BHMT | |
| Serine SCHEMBL8696833 | 0.89 | BHMT (0.40) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL5193805 | 0.87 | METAP2 (0.42) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL1289285 | 0.86 | METAP2 (0.38) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL1352749 | 0.86 | SLC7A5 (0.42) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL11531701 | 0.85 | RNPEP (0.37) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL28729561 | 0.85 | METAP2 (0.43) | METAP2METAP1RNPEPMARS1BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106834262-B | A kind of linoleate isomerase mutant and its application | 杭州师范大学 | 2019-08-16 | — | — | CN | claimed |
| CN-106834262-A | A kind of linoleate isomerase mutant and its application | 杭州师范大学 | 2017-06-13 | — | — | CN | claimed |
| CN-108642025-A | The lipase mutant and its application that a kind of enzyme activity and regioselectivity improve | 江南大学 | 2018-10-12 | — | — | CN | disclosed |
| EP-2802661-A1 | MUTATED CEPHALOSPORIN HYDROXYLASE AND ITS APPLICATION IN DEACETYLCEPHALOSPORANIC ACID SYNTHESIS | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2014-11-19 | — | — | EP | disclosed |
| EP-2729570-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | Qiagen GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013105030-A1 | MUTATED CEPHALOSPORIN HYDROXYLASE AND ITS APPLICATION IN DEACETYLCEPHALOSPORANIC ACID SYNTHESIS | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013004710-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2121725-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | Novo Nordisk Health Care AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-7582424-B2 | Accessory cholera enterotoxin and analogs thereof as activators of calcium dependent chloride channel | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2008098958-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-21 | — | — | WO | disclosed |
| EP-1465908-A2 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1365786-A2 | ACCESSORY CHOLERA ENTEROTOXIN AND ANALOGS THEREOF AS ACTIVATORS OF CALCIUM DEPENDENT CHLORIDE CHANNEL | Trucksis, Michele (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2003057830-A2 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2002009642-A9 | ACCESSORY CHOLERA ENTEROTOXIN AND ANALOGS THEREOF AS ACTIVATORS OF CALCIUM DEPENDENT CHLORIDE CHANNEL | UNIV MARYLAND (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2002009642-A2 | ACCESSORY CHOLERA ENTEROTOXIN AND ANALOGS THEREOF AS ACTIVATORS OF CALCIUM DEPENDENT CHLORIDE CHANNEL | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2000015605-A2 | CHIRAL CYANOAMINES AND METHODS OF PREPARATION | TRUSTEES OF BOSTON COLLEGE (US) | 2000-03-23 | — | — | WO | disclosed |
| EP-0975798-A1 | METHOD TO DIAGNOSE AND TREAT PATHOLOGICAL CONDITIONS RESULTING FROM DEFICIENT ION TRANSPORT SUCH AS PSEUDOHYPOALDOSTERONISM TYPE-1 | YALE UNIVERSITY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998040516-A1 | METHOD TO DIAGNOSE AND TREAT PATHOLOGICAL CONDITIONS RESULTING FROM DEFICIENT ION TRANSPORT SUCH AS PSEUDOHYPOALDOSTERONISM TYPE-1 | YALE UNIVERSITY (US) | 1998-09-17 | — | — | WO | disclosed |
| US-4345032-A | THIOAMINOACIDS, FECES | SEIKENKAI (JP) | 1982-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | PTMS, DNPEP, VIP | METAP2 34/4885METAP1 64/4885RNPEP 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.